MG001: Could a Kratom-Derived Medication Become a New Treatment for Opioid Withdrawal?

Key Points

• MG001 is an experimental pharmaceutical formulation of mitragynine, the primary psychoactive alkaloid found in the kratom plant.
• In June 2026, the National Institutes of Health (NIH) announced that the FDA had allowed its investigational new drug application for mitragynine to take effect, permitting human clinical research to proceed.
• The first registered clinical trial, NCT07204171, is designed to evaluate MG001’s safety, tolerability, and pharmacokinetics in approximately 32 adult participants.
• Researchers are investigating whether mitragynine could eventually provide another medication option for opioid use disorder, but MG001 has not been proven effective for withdrawal or addiction in humans.
• MG001 differs from concentrated 7-hydroxymitragynine (7-OH) products, although the body can metabolize mitragynine into 7-OH.
• FDA-approved alternatives are already available: Although MG001 remains experimental, FDA-approved medications such as buprenorphine, methadone, and naltrexone are established options for opioid use disorder.
• Brooks Healing Center offers evidence-based Medication-Assisted Treatment (MAT) using FDA-approved medications, including extended-release injectable buprenorphine options such as Sublocade and Brixadi, when clinically appropriate.
• How Brooks Healing Center helps: Brooks provides medical detox, residential addiction treatment, medication-assisted treatment, partial hospitalization, and continuing recovery support for individuals struggling with opioid dependence, kratom use, and concentrated 7-OH products.

For years, kratom has occupied a complicated position in conversations about opioid addiction. Some individuals report using the plant to manage pain, reduce opioid cravings, or make withdrawal symptoms more tolerable. Meanwhile, medical researchers and federal health agencies have raised concerns about physical dependence, inconsistent product composition, and the growing availability of concentrated kratom-derived opioids.

Now, a pharmaceutical research initiative could help answer whether one of kratom’s primary compounds has a legitimate place in addiction medicine. In June 2026, the National Institutes of Health announced that researchers had received authorization to begin human clinical research involving a purified formulation of mitragynine.

That investigational medication is known as MG001, and its development represents an important distinction between studying the potential medical applications of kratom alkaloids and recommending commercially available kratom products for treating addiction.

Could MG001 eventually become another medication for opioid withdrawal or opioid use disorder? The research offers an interesting possibility, but the clinical evidence needed to establish its effectiveness has not yet been produced. In the meantime, FDA-approved medications for opioid use disorder are already available through established treatment programs, including the Medication-Assisted Treatment program at Brooks Healing Center in Tennessee.

What Is MG001?

An Experimental Mitragynine Medication Being Studied by the NIH

MG001 is an investigational oral medication containing a purified formulation of mitragynine. Mitragynine is the most abundant psychoactive alkaloid found in Mitragyna speciosa, the Southeast Asian tree commonly known as kratom.

Unlike ordinary kratom powders, extracts, or concentrated products sold commercially, MG001 is being developed as a pharmaceutical research formulation. Researchers can evaluate a defined substance under controlled conditions rather than relying on botanical preparations that may contain varying concentrations of multiple active compounds.

The National Institute on Drug Abuse (NIDA), part of the NIH, is sponsoring the first registered human clinical trial of MG001. Researchers at the NIH and University of Florida contributed to developing the formulation and the preclinical research supporting its investigational new drug application.

On June 1, 2026, the NIH announced that the FDA had allowed the investigational new drug application for mitragynine to take effect. This regulatory step permits authorized human research to proceed, but it should not be confused with FDA approval to prescribe or commercially market MG001.

The long-term goal is to investigate whether mitragynine could eventually become a useful medication for people experiencing opioid use disorder. However, the initial research must first establish fundamental information about how the formulation behaves in humans.

MG001 at a Glance

Clinical Development, Pharmacology, and Potential Medical Applications

The registered clinical trial is titled Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral MG001. Its official registration number is NCT07204171.

The study record’s last posted update, dated June 16, 2026, listed the trial as not yet recruiting and provided an estimated completion date of April 2027. These are planning details rather than evidence that the trial has been completed or that its outcomes are known.

Why Is the NIH Investigating a Compound From Kratom?

Understanding the Search for Additional Opioid Addiction Medications

Opioid use disorder remains a significant public health challenge, and researchers continue investigating medications that could improve treatment access, reduce overdose deaths, and help people maintain recovery. Although effective medications already exist, not everyone receives them, remains engaged in treatment, or experiences the same response.

Medications such as buprenorphine and methadone have substantial evidence supporting their effectiveness. Nevertheless, researchers are interested in whether additional treatments could offer different pharmacological properties, improve accessibility, or benefit patients whose needs are not adequately addressed by existing options.

Kratom attracted scientific attention partly because some people have reported using it independently to reduce opioid withdrawal symptoms. These reports have generated hypotheses about the plant’s pharmacology, but personal experiences and observational findings are not equivalent to controlled evidence demonstrating that kratom safely treats opioid use disorder.

Researchers have therefore investigated mitragynine separately from the botanical plant. Mitragynine interacts with opioid receptors, and some preclinical studies have suggested that its biological effects differ from those of conventional opioid medications.

According to the NIH’s June 2026 announcement, preclinical research involving mitragynine did not identify significant safety concerns across several tested conditions in animal models. These findings contributed to the decision to proceed with human safety research.

However, results from laboratory and animal studies cannot establish whether a medication will be safe, effective, or appropriate for people with opioid use disorder. Those questions require carefully designed human clinical trials.

How Does MG001 Work in the Brain?

Mitragynine, Mu-Opioid Receptors, and the Role of Metabolism

MG001 contains mitragynine, an alkaloid capable of influencing the mu-opioid receptor system. These receptors are involved in pain perception, reward, sedation, and the development of physical dependence associated with opioid exposure.

Mitragynine has been described as an atypical opioid-active compound because its pharmacological properties differ from those of several conventional opioids. Its effects involve opioid receptor signaling and additional biological mechanisms that researchers continue to investigate.

An important finding from earlier research concerns what happens after mitragynine enters the body. In 2019, researchers published a study in ACS Central Science demonstrating that mitragynine can be metabolized into 7-hydroxymitragynine, commonly called 7-OH.

Using laboratory experiments involving human and mouse liver preparations, researchers identified cytochrome P450 enzymes, particularly CYP3A4 in human systems, as important contributors to this conversion.

The study also found that the formation of 7-OH played a substantial role in the pain-relieving effects of mitragynine in mice. However, the extent to which these findings translate to humans remains an important research question.

These findings matter for MG001 because an investigational medication containing mitragynine must be evaluated not only for the effects of the original compound but also for the effects of metabolites produced after administration.

Individual differences in metabolism, liver function, medication exposure, and other biological characteristics could influence how people respond to a mitragynine-based medication. Researchers need clinical evidence to understand these relationships before determining whether MG001 has an acceptable therapeutic profile.

MG001 vs. 7-OH: What Is the Difference?

Why Purified Mitragynine Research Is Different From Concentrated Kratom-Derived Opioid Products

One of the most important distinctions in this research involves the difference between mitragynine and 7-hydroxymitragynine.

Although the two compounds are chemically related, they are not identical. Mitragynine is the predominant alkaloid in natural kratom leaves, while 7-OH is generally present in much smaller natural quantities and demonstrates greater potency at mu-opioid receptors in experimental research.

Commercial products containing concentrated 7-OH are also fundamentally different from the controlled pharmaceutical formulation being studied as MG001.

The FDA has repeatedly warned consumers about products containing added or enhanced concentrations of 7-OH. These products are commonly marketed as tablets, gummies, shots, and other convenient formulations, sometimes alongside traditional kratom supplements.

According to the FDA’s consumer guidance, concentrated 7-OH products have not been proven safe or effective for any medical purpose. The agency has raised concerns about opioid-like effects, dependence, misuse, and serious adverse outcomes.

The investigation of MG001 does not contradict those warnings. Scientific research into a carefully controlled formulation can occur alongside public health restrictions on unapproved consumer products.

Furthermore, because mitragynine can be metabolized into 7-OH, researchers cannot assume that purified mitragynine is free from opioid-related risks. Instead, the conversion process is one of the pharmacological characteristics that requires careful investigation.

What Is the MG001 Clinical Trial Investigating?

Understanding the First Phase 1 Study of Oral MG001

The first registered clinical trial of MG001 is designed to investigate fundamental safety and pharmacological questions rather than determine whether the medication successfully treats addiction.

The trial is sponsored by NIDA and is designed to enroll approximately 32 healthy adult participants who satisfy specified medical and eligibility requirements. Although the eventual development goal involves opioid use disorder, the initial study is not designed to establish treatment effectiveness in patients with that condition.

Participants are randomly assigned to receive either MG001 or an inactive placebo. The study uses a double-blind design, meaning treatment assignment is concealed from participants and designated research personnel to reduce bias.

Researchers are investigating several outcomes:

• Safety: Whether participants experience concerning physiological changes, adverse events, or other medically significant reactions.
• Tolerability: How participants respond to the investigational medication under controlled conditions.
• Pharmacokinetics: How the medication is absorbed, distributed, metabolized, and eliminated.
• Drug exposure: How measured concentrations change over time after administration.
• Dose-related responses: Whether exposure and observed effects change across the study’s planned dose groups.

Participants undergo clinical monitoring and laboratory assessments following administration. These evaluations are intended to provide researchers with early human data needed to inform possible future investigations.

Importantly, the trial does not establish whether MG001 reduces opioid cravings, prevents withdrawal, improves treatment retention, or decreases overdose risk. Those outcomes would require additional clinical studies designed specifically to measure treatment effectiveness.

Could MG001 Eventually Treat Opioid Withdrawal?

What Researchers Hope to Discover About Mitragynine and Opioid Dependence

The potential application of MG001 in opioid withdrawal treatment is one of the most interesting aspects of its development. Because mitragynine influences opioid-related biological pathways, researchers are investigating whether it might eventually provide clinically useful effects for people experiencing opioid use disorder.

However, a medication that affects opioid receptors does not automatically become an effective or appropriate addiction treatment. Researchers must evaluate whether it produces meaningful benefits, how it compares with established medications, and whether those benefits outweigh its risks.

For MG001 to become a viable treatment option, future clinical research would need to address several questions:

• Can it reliably reduce opioid withdrawal symptoms?
• Does it meaningfully reduce cravings for other opioids?
• Can patients use it without developing problematic patterns of misuse or escalating dependence?
• What effects does it have on breathing, sedation, and cognitive functioning?
• How does it interact with other medications?
• Does it improve treatment retention or other meaningful recovery outcomes?
• How does its overall safety and effectiveness compare with existing medications?

It is also important to distinguish physical dependence from opioid use disorder. Physical dependence can occur with prescribed medications, while opioid use disorder involves a broader pattern of impaired control, continued use despite harm, and other clinical symptoms.

An effective medication for opioid use disorder does not necessarily need to eliminate all physical dependence. Rather, its benefits must be demonstrated through clinically meaningful outcomes such as reduced harmful opioid use, improved functioning, and decreased overdose risk.

At present, MG001 remains an investigational compound. The existing evidence does not justify using commercial kratom, purified mitragynine purchased outside research settings, or concentrated 7-OH products as substitutes for established addiction medications.

MG001 vs. FDA-Approved Medications for Opioid Use Disorder

How Experimental Mitragynine Research Compares to Established Medication-Assisted Treatment

Although MG001 represents an interesting area of addiction medicine research, it is important to distinguish experimental medications from treatments that have already undergone extensive clinical testing and received FDA approval. MG001 has not been approved to treat opioid withdrawal, opioid use disorder, or any other medical condition. Its potential effectiveness and long-term safety remain under investigation.

Individuals experiencing opioid dependence do not need to rely on experimental medications to access effective treatment. The FDA has approved three primary medications for opioid use disorder: buprenorphine, methadone, and naltrexone. These medications have established clinical applications and can help reduce opioid-related harms when appropriately prescribed and managed.

At Brooks Healing Center, our Medication-Assisted Treatment (MAT) program incorporates FDA-approved medications into individualized addiction treatment plans. This includes buprenorphine-based medications and long-acting injectable treatment options such as Sublocade® and Brixadi® when clinically appropriate.

The difference between MG001 and these established treatments is not simply that they were developed at different times. Buprenorphine, methadone, and naltrexone have undergone extensive clinical evaluation, and their benefits, risks, limitations, and appropriate applications are supported by established medical evidence.

For people experiencing opioid use disorder, medication selection should be based on individual clinical needs, previous treatment experiences, current substance exposure, and recovery goals rather than assumptions about whether one medication is universally better than another.

Injectable Buprenorphine: Sublocade and Brixadi at Brooks Healing Center

FDA-Approved Long-Acting Medications That Support Opioid Addiction Recovery

Two important options within modern opioid addiction treatment are Sublocade and Brixadi. Both medications contain buprenorphine, a partial mu-opioid receptor agonist with extensive clinical evidence supporting its use in opioid use disorder treatment. Unlike experimental compounds such as MG001, these medications have undergone regulatory review and are FDA-approved for their indicated uses.

Buprenorphine helps stabilize opioid receptor activity, which can reduce withdrawal symptoms, decrease cravings, and support continued engagement in treatment. Long-acting injectable formulations provide another delivery option for individuals who may benefit from medication administered by a healthcare professional rather than taking a daily oral or sublingual product.

What Is Sublocade?

Sublocade is an FDA-approved extended-release buprenorphine injection administered monthly by a qualified healthcare professional. It delivers medication gradually over time, helping manage withdrawal symptoms and cravings without requiring patients to take a daily buprenorphine product throughout maintenance treatment.

Sublocade may be appropriate for individuals who benefit from consistent medication exposure and a monthly administration schedule. Patients must meet the medication’s prescribing and initiation requirements, including appropriate assessment of buprenorphine tolerability.

The FDA’s current prescribing information permits appropriately supervised initiation after a qualifying transmucosal buprenorphine dose for eligible new patients, as well as transition from ongoing transmucosal buprenorphine treatment. The appropriate pathway is determined by the prescribing clinician.

At Brooks Healing Center, Sublocade may be incorporated into an individualized treatment plan alongside therapy, relapse-prevention work, recovery education, and continued support.

What Is Brixadi?

Brixadi is another FDA-approved extended-release buprenorphine injection, but it offers both weekly and monthly formulations. This provides additional flexibility for medical providers when developing individualized treatment plans.

For patients who are not already receiving buprenorphine, the FDA-approved initiation pathway involves establishing tolerability with transmucosal buprenorphine before starting the weekly Brixadi formulation. The monthly formulation is used according to its prescribing requirements and the patient’s treatment history.

Brixadi can support recovery by providing sustained buprenorphine exposure without requiring daily medication administration. Depending on individual circumstances, its weekly or monthly formulations may be appropriate during stabilization or ongoing treatment.

At Brooks Healing Center, Brixadi is an available MAT option for clinically appropriate patients. Our medical team evaluates medication history, current opioid exposure, withdrawal symptoms, and recovery goals before making treatment recommendations.

Sublocade vs. Brixadi: How Do These Injectable Buprenorphine Medications Differ?

Both medications must be administered by qualified healthcare professionals under applicable safety requirements. They are not interchangeable without appropriate medical evaluation, and the choice between them depends on clinical history, current opioid exposure, treatment goals, and other individual factors.

For eligible patients, long-acting injectable medications can offer important practical advantages, including consistent medication delivery, fewer daily medication-management responsibilities, and reduced opportunities for medication diversion. However, these medications still carry opioid-related risks and require appropriate clinical oversight.

Importantly, neither medication is an approved treatment specifically for kratom dependence. Their FDA approval applies to opioid use disorder, and any medication decisions involving kratom or 7-OH dependence require individualized medical assessment.

Medication-Assisted Treatment Is Not Limited to One Level of Care

How Brooks Integrates FDA-Approved Medications Into Individualized Addiction Treatment

At Brooks Healing Center, medication-assisted treatment is not exclusively associated with a single level of addiction care. FDA-approved medications may be incorporated into individualized treatment plans during medical detox, residential treatment, and appropriate continuing treatment or step-down planning.

Our approach recognizes that stabilizing opioid withdrawal and cravings is only one component of recovery. Medication support can be combined with individual counseling, group therapy, trauma-informed care, relapse-prevention education, and ongoing recovery planning.

For someone entering treatment with significant physical dependence, medical detox may provide an appropriate environment for withdrawal assessment, stabilization, and medication evaluation. Other patients may already be receiving buprenorphine or another medication for opioid use disorder when they begin treatment.

During residential addiction treatment, medication management can be coordinated alongside behavioral therapies that address cravings, triggers, emotional regulation, and the circumstances contributing to repeated substance use.

As patients transition into the Partial Hospitalization Program (PHP) or another appropriate continuing-care arrangement, ongoing medication support and coordination with prescribing providers may remain important parts of recovery.

People seeking opioid addiction treatment may have different medication needs depending on whether their substance use involves prescription opioids, heroin, fentanyl, or other opioid-active compounds. Brooks also provides specialized treatment information for individuals struggling with fentanyl addiction and kratom and 7-OH dependence.

Brooks does not operate a methadone-dispensing opioid treatment program. When clinically appropriate, the team may coordinate care with outside providers for patients receiving methadone.

The distinction between MG001 and currently available treatments is straightforward: MG001 is an experimental pharmaceutical formulation whose clinical benefits remain uncertain, while medications such as Sublocade and Brixadi are FDA-approved options supported by clinical research. Individuals seeking help with opioid dependence can access established treatment approaches today rather than waiting for experimental medications to complete the clinical development process.

Does MG001 Research Mean Kratom Is Safe?

Why Pharmaceutical Development Does Not Validate Unregulated Kratom Products

The short answer is no. Investigating a substance’s potential medical applications does not establish that commercially available products containing related ingredients are safe.

Many established medications originated from plants or naturally occurring chemicals. However, a botanical source is only the beginning of the scientific process. Pharmaceutical development requires researchers to investigate chemical composition, manufacturing consistency, pharmacology, toxicity, clinical effectiveness, and appropriate monitoring.

Traditional kratom leaves contain numerous alkaloids, while commercial extracts may concentrate particular compounds. Other products may contain added 7-OH or ingredients that are not accurately represented on the label.

These differences can substantially change the pharmacological effects of a product. Someone consuming a commercial kratom extract cannot assume they are receiving the same exposure that researchers are studying through MG001.

The FDA continues to warn about potentially serious adverse effects associated with kratom, including liver toxicity, seizures, physical dependence, withdrawal, and substance use disorder. The agency also distinguishes traditional botanical kratom from concentrated 7-OH products, which have become a separate and significant public health concern.

The existence of a clinical trial should therefore be interpreted as evidence that researchers believe a question is worth investigating, not that they already know the answer.

Can Mitragynine Cause Addiction or Withdrawal?

Understanding Opioid Receptor Activity and the Risks of Repeated Kratom Use

Mitragynine and other kratom alkaloids interact with biological pathways involved in opioid effects. Although the complete pharmacology of mitragynine remains under investigation, repeated kratom use has been associated with physical dependence, tolerance, and withdrawal symptoms in some individuals.

People who regularly use kratom may begin taking it for pain, energy, relaxation, or relief from previous opioid withdrawal. Over time, some develop a pattern of repeated use that is increasingly driven by the need to prevent uncomfortable symptoms between doses.

Potential signs of problematic kratom use include:

• Needing increasingly frequent doses to maintain the same perceived effects.
• Experiencing anxiety, restlessness, sweating, gastrointestinal symptoms, or sleep problems when attempting to stop.
• Using kratom primarily to prevent withdrawal rather than for its original intended purpose.
• Repeated unsuccessful attempts to reduce or discontinue use.
• Continuing despite financial, emotional, physical, or relationship problems.
• Progressing from traditional leaf products to concentrated extracts or 7-OH.
• Combining kratom products with prescription opioids, alcohol, or other substances.

These symptoms do not occur in every person who uses kratom, and their severity varies. However, a botanical product’s availability or traditional history does not eliminate the possibility of substance use disorder.

Someone experiencing dependence on kratom or concentrated 7-OH may benefit from medical assessment, particularly when withdrawal symptoms are significant, other substances are involved, or previous attempts to stop have been unsuccessful.

Brooks Healing Center provides additional information about these concerns in our kratom addiction treatment guide and our article explaining 7-OH withdrawal symptoms and treatment considerations.

What Could MG001 Mean for the Future of Addiction Medicine?

New Research May Expand Treatment Options, but Clinical Evidence Must Come First

MG001 represents an interesting development because it demonstrates that researchers are willing to investigate pharmacological properties associated with a controversial substance rather than treating every related compound as scientifically identical.

One longstanding challenge in addiction medicine is the need to distinguish a substance’s potential therapeutic properties from the harms associated with uncontrolled use. This distinction has been important throughout the development of many medications that affect opioid receptors.

The future of MG001 will depend on the results of clinical studies. Researchers must determine whether the formulation has an acceptable safety profile before establishing whether it can produce meaningful benefits for people with opioid use disorder.

Even if preliminary safety results are encouraging, additional trials would be needed to evaluate effectiveness, appropriate clinical use, adverse effects, drug interactions, and outcomes over time.

Successful clinical development could eventually expand the available treatment options. Unfavorable safety or effectiveness findings could also establish important limitations and help prevent inappropriate medical use.

Either outcome would contribute to a more evidence-based understanding of mitragynine and its potential role in addiction medicine.

Treatment for Kratom and Opioid Dependence in Tennessee

How Brooks Healing Center Supports Withdrawal Management and Long-Term Recovery

While research into MG001 continues, people experiencing opioid dependence or problematic kratom use do not need to rely on experimental substances to begin treatment. Established medical and behavioral approaches can address withdrawal, cravings, relapse risk, and the broader circumstances contributing to substance use.

Brooks Healing Center provides individualized addiction treatment in Normandy, Tennessee, between Nashville and Chattanooga. Our programs support adults experiencing opioid use disorder, kratom dependence, concentrated 7-OH use, and appropriate co-occurring mental health concerns.

Treatment planning considers the person’s medical history, substances used, physical dependence, mental health needs, previous treatment experiences, and recovery goals. Depending on clinical assessment, appropriate services may include:

• Medical Detox: Supervised withdrawal management, medical monitoring, symptom assessment, and stabilization.
• Residential Treatment: Structured addiction treatment incorporating individual counseling, group therapy, behavioral interventions, and recovery planning.
• Medication-Assisted Treatment: Individualized evaluation of appropriate FDA-approved medications, including buprenorphine-based options such as Sublocade and Brixadi for eligible patients with opioid use disorder.
• Partial Hospitalization Program: Continued intensive clinical treatment for individuals who no longer require around-the-clock residential care.
• Continuing Recovery Support: Recovery-focused housing options, relapse-prevention planning, peer support, and aftercare coordination.

Some people seeking treatment began using kratom to manage withdrawal from other opioids. Others developed dependence after using kratom products for unrelated reasons such as chronic pain, anxiety, fatigue, or sleep problems.

Understanding those differences is important. Treatment should address the reasons substance use began, the factors that allowed it to continue, and the support needed to maintain progress after withdrawal symptoms improve.

For someone experiencing opioid use disorder, FDA-approved medications can help address the biological aspects of dependence while behavioral treatment provides additional support for long-term recovery. Brooks’ MAT program is designed to make medication support part of an individualized treatment plan rather than treating it as a separate or competing approach.

Get Help for Opioid or Kratom Dependence

Speak With Brooks Healing Center About FDA-Approved Medication-Assisted Treatment

The investigation of MG001 may eventually lead to new developments in addiction medicine. However, experimental pharmaceutical research does not replace the medications and treatment approaches already available to people struggling with opioid use disorder.

At Brooks Healing Center, patients can access evidence-based treatment that includes FDA-approved medication options when clinically appropriate. Our Medication-Assisted Treatment program supports individualized recovery plans using medications such as buprenorphine, including long-acting injectable options like Sublocade and Brixadi.

If you or someone you care about is experiencing opioid withdrawal, dependence on kratom or concentrated 7-OH, or difficulty stopping repeated substance use, Brooks Healing Center can help you understand available treatment options.

Our admissions team can discuss your circumstances, explain appropriate levels of care, and help verify insurance benefits before treatment.

CALL NOW: 931-486-8824
Verify Your Insurance

Frequently Asked Questions About MG001

MG001 Research, FDA Approval, and Opioid Addiction Treatment

What Is MG001?

MG001 is an investigational oral medication containing a purified formulation of mitragynine, the primary psychoactive alkaloid found in kratom. The NIH is investigating the formulation as a potential future medication for opioid use disorder. Its first registered human clinical trial focuses on safety, tolerability, and pharmacokinetics rather than establishing treatment effectiveness.

Is MG001 Made From Kratom?

MG001 contains mitragynine, a compound originally identified in the kratom plant. However, MG001 is a defined pharmaceutical research formulation rather than traditional kratom leaf, powder, or extract. Its controlled composition and research setting distinguish it from commercially marketed botanical products.

Is MG001 FDA Approved?

No. MG001 is not an FDA-approved medication. The FDA allowed an investigational new drug application involving mitragynine to take effect in 2026, permitting authorized human research to proceed. This authorization does not establish that the medication is safe or effective for treating opioid withdrawal or opioid use disorder.

Can MG001 Treat Opioid Withdrawal?

Researchers are investigating whether MG001 could eventually become a treatment for opioid use disorder, but its effectiveness has not been established in humans. The initial Phase 1 clinical trial is intended to gather safety and pharmacokinetic data. Additional clinical trials would be needed before determining whether it reduces withdrawal symptoms, cravings, or harmful opioid use.

Is MG001 the Same as 7-Hydroxymitragynine?

No. MG001 contains mitragynine, whereas 7-hydroxymitragynine, commonly called 7-OH, is a different compound. The body can convert some mitragynine into 7-OH through metabolic processes, but this does not make the original compounds interchangeable. Concentrated commercial 7-OH products are also different from the controlled formulation used in MG001 research.

Can You Buy MG001?

MG001 is not available as an FDA-approved prescription medication or an established over-the-counter treatment. It is an investigational formulation being evaluated through authorized clinical research. Commercial products claiming to contain mitragynine should not be assumed to have the same composition, safety characteristics, or regulatory status.

Is MG001 Better Than Suboxone?

There is no clinical evidence demonstrating that MG001 is more effective or safer than Suboxone, a medication containing buprenorphine and naloxone. Buprenorphine-based medications have substantial evidence supporting their use in opioid use disorder treatment. MG001 remains experimental, and comparative clinical effectiveness has not been established.

Does Brooks Healing Center Offer FDA-Approved Alternatives to MG001?

Yes. Although MG001 remains an experimental medication and is not FDA-approved, Brooks Healing Center offers an evidence-based Medication-Assisted Treatment program incorporating approved medications for opioid use disorder. Treatment options include buprenorphine-based medications such as Sublocade and Brixadi. Medical providers determine medication eligibility and treatment recommendations based on each patient’s individual circumstances.

Are Sublocade and Brixadi FDA-Approved for Opioid Withdrawal and Addiction?

Yes. Sublocade and Brixadi are FDA-approved extended-release buprenorphine medications for opioid use disorder. Both can help manage withdrawal symptoms and cravings as part of comprehensive treatment, although they differ in their dosing schedules and initiation requirements. Sublocade is administered monthly, while Brixadi offers weekly and monthly formulations. Brooks Healing Center incorporates these medications into individualized treatment plans when clinically appropriate, alongside counseling, behavioral therapies, and recovery support.

Is Sublocade Better Than Brixadi?

Neither medication is universally better for every patient. Sublocade and Brixadi both contain buprenorphine but use different extended-release delivery systems and administration schedules. Sublocade is administered monthly, while Brixadi offers weekly and monthly formulations. The most appropriate option depends on clinical history, treatment goals, previous buprenorphine exposure, and the prescribing provider’s assessment.

Can Injectable Buprenorphine Help With Fentanyl Addiction?

Yes. Extended-release buprenorphine medications such as Sublocade and Brixadi are approved to treat opioid use disorder, including OUD involving fentanyl. However, fentanyl exposure can complicate medication initiation for some patients. A qualified medical provider should evaluate the appropriate timing and treatment approach. Learn more about fentanyl addiction treatment at Brooks Healing Center.

Does MG001 Prove Kratom Can Treat Addiction?

No. The clinical investigation of purified mitragynine does not prove that kratom products safely or effectively treat opioid addiction. Botanical kratom, concentrated extracts, and enhanced 7-OH products can have different chemical compositions and risks. MG001 is being studied precisely because more controlled scientific evidence is needed.

When Will MG001 Clinical Trial Results Be Available?

The MG001 Phase 1 study is registered under ClinicalTrials.gov identifier NCT07204171. The study record last updated in June 2026 listed an estimated primary completion date of March 2027 and an estimated overall completion date of April 2027. These dates may change, and completion does not necessarily mean that results will become publicly available immediately.

Can Brooks Healing Center Treat Kratom and 7-OH Dependence?

Yes. Brooks Healing Center provides individualized treatment for substance use problems involving kratom, concentrated 7-OH, and other opioid-active substances. Depending on medical and clinical needs, treatment may include supervised withdrawal management, residential addiction treatment, medication assessment, therapy, PHP, and continuing recovery support. There is currently no FDA-approved medication specifically for kratom dependence, so medication decisions are individualized and may differ from treatment for a separately diagnosed opioid use disorder.

Related Resources

Further Reading About Kratom, 7-OH, and Emerging Opioid Research

• 7-OH Withdrawal: Symptoms, Duration, and What Actually Helps
• Mitragynine Pseudoindoxyl vs. 7-Hydroxymitragynine: What’s the Difference?
• Is Pseudoindoxyl Stronger Than 7-OH? What This Kratom Compound Actually Does
• MGM-15: What to Know About This Kratom-Derived Opioid
• MGM-16 vs. MGM-15: Understanding Synthetic Kratom-Derived Opioids
• Kratom and 7-OH Ban by State: Understanding Current Restrictions

Related Treatment Pages

FDA-Approved Medications, Addiction Treatment, and Recovery Support at Brooks

• Medication-Assisted Treatment (MAT) in Tennessee
• Sublocade Injections for Opioid Use Disorder
• Brixadi Injections for Opioid Addiction Treatment
• Opioid Addiction Treatment in Tennessee
• Fentanyl Addiction Treatment and Detox
• Kratom and 7-OH Addiction Treatment
• Medical Detox in Tennessee
• Residential Addiction Treatment
• Partial Hospitalization Program (PHP)
• Insurance Verification for Addiction Treatment

References

Clinical Research, Peer-Reviewed Studies, and Government Sources (APA Format)

Kruegel, A. C., Uprety, R., Grinnell, S. G., Langreck, C., Pekarskaya, E. A., Le Rouzic, V., Ansonoff, M., Gassaway, M. M., Pintar, J. E., Pasternak, G. W., Javitch, J. A., Majumdar, S., & Sames, D. (2019). 7-Hydroxymitragynine is an active metabolite of mitragynine and a key mediator of its analgesic effects. ACS Central Science, 5(6), 992–1001. https://pmc.ncbi.nlm.nih.gov/articles/PMC6598159/

National Center for Complementary and Integrative Health. (n.d.). Kratom. National Institutes of Health. https://www.nccih.nih.gov/health/kratom

National Institute on Drug Abuse. (2026). Phase 1 study of oral MG001 (ClinicalTrials.gov identifier NCT07204171). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07204171

National Institutes of Health. (2018, June 19). Methadone and buprenorphine reduce risk of death after opioid overdose. https://www.nih.gov/news-events/news-releases/methadone-buprenorphine-reduce-risk-death-after-opioid-overdose

National Institutes of Health. (2026, June 1). NIH research clears way for study of experimental treatment for opioid use disorder. https://www.nih.gov/news-events/news-releases/nih-research-clears-way-study-experimental-treatment-opioid-use-disorder

U.S. Food and Drug Administration. (2023, May 23). FDA approves new buprenorphine treatment option for opioid use disorder. https://www.fda.gov/news-events/press-announcements/fda-approves-new-buprenorphine-treatment-option-opioid-use-disorder

U.S. Food and Drug Administration. (2026). Information about medications for opioid use disorder (MOUD). https://www.fda.gov/drugs/food-and-drug-administration-overdose-prevention-framework/information-about-medications-opioid-use-disorder-moud

U.S. Food and Drug Administration. (n.d.). FDA and kratom. https://www.fda.gov/news-events/public-health-focus/fda-and-kratom

U.S. Food and Drug Administration. (2025). Products containing 7-OH can cause serious harm. https://www.fda.gov/consumers/consumer-updates/products-containing-7-oh-can-cause-serious-harm

U.S. National Library of Medicine. (2025). Brixadi (buprenorphine) extended-release injection: Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d8a8fd0-8619-422a-a664-d1d2e8970f48